Press release
Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics
"Adrenoleukodystrophy Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.
The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.
*
Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment
*
Emerging Adrenoleukodystrophy therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.
Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.
Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight [https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:
*
ABX-002: Autobahn Therapeutics
*
VK0214: Viking Therapeutics
*
SBT101: SwanBio Therapeutics
*
PXL065: Poxel SA
*
PXL770: Poxel SA
*
Leriglitazone : Minoryx Therapeutics
*
OP101 : Orpheris
*
Leriglitazone (MIN102): Minoryx Therapeutics
Route of Administration
Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Molecule Type
Products have been categorized under various Molecule types, such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Adrenoleukodystrophy Pipeline Therapeutics Assessment
*
Adrenoleukodystrophy Assessment by Product Type
*
Adrenoleukodystrophy By Stage and Product Type
*
Adrenoleukodystrophy Assessment by Route of Administration
*
Adrenoleukodystrophy By Stage and Route of Administration
*
Adrenoleukodystrophy Assessment by Molecule Type
*
Adrenoleukodystrophy by Stage and Molecule Type
DelveInsight's Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:
Key companies developing therapies for Adrenoleukodystrophy are - AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.
Adrenoleukodystrophy Pipeline Analysis:
The Adrenoleukodystrophy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.
*
Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Adrenoleukodystrophy Pipeline Market Drivers
*
Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.
Adrenoleukodystrophy Pipeline Market Barriers
*
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.
Scope of Adrenoleukodystrophy Pipeline Drug Insight
*
Coverage: Global
*
Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
*
Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
*
Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies
*
Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers
Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Adrenoleukodystrophy Report Introduction
2
Adrenoleukodystrophy Executive Summary
3
Adrenoleukodystrophy Overview
4
Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5
Adrenoleukodystrophy Pipeline Therapeutics
6
Adrenoleukodystrophy Late Stage Products (Phase II/III)
7
Adrenoleukodystrophy Mid Stage Products (Phase II)
8
Adrenoleukodystrophy Early Stage Products (Phase I)
9
Adrenoleukodystrophy Preclinical Stage Products
10
Adrenoleukodystrophy Therapeutics Assessment
11
Adrenoleukodystrophy Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Adrenoleukodystrophy Key Companies
14
Adrenoleukodystrophy Key Products
15
Adrenoleukodystrophy Unmet Needs
16
Adrenoleukodystrophy Market Drivers and Barriers
17
Adrenoleukodystrophy Future Perspectives and Conclusion
18
Adrenoleukodystrophy Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenoleukodystrophy-pipeline-update-2024-fda-approvals-therapeutic-advancements-by-delveinsight-autobahn-therapeutics-viking-therapeutics-swanbio-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics here
News-ID: 3558727 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Adrenoleukodystrophy
Adrenoleukodystrophy Treatment Market: Transforming Rare Disease Therapeutics
The adrenoleukodystrophy treatment market was valued at approximately USD 1.1 billion in 2023 and is anticipated to reach around USD 2.4 billion by 2033, growing at a CAGR of 8.1% from 2024 to 2033.
The adrenoleukodystrophy (ALD) treatment market represents a critical segment within the rare disease therapeutics landscape, addressing one of the most challenging genetic disorders affecting the nervous system and adrenal glands. This X-linked genetic condition, caused by mutations…
X Linked Adrenoleukodystrophy Market Regional Analysis & Global Forecast to 2025 …
The X-Linked Adrenoleukodystrophy Market Is Set To Grow At An Estimated CAGR Of 14% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $4.5 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of X Linked Adrenoleukodystrophy market goods. The market study excludes key regions that are accelerating marketization. This…
X-linked Adrenoleukodystrophy Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "X-Linked Adrenoleukodystrophy Pipeline Insight, 2024," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-Linked Adrenoleukodystrophy (X-ALD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in X-linked adrenoleukodystrophy Research. Learn more…
Adrenoleukodystrophy Pipeline Outlook, Clinical Trials, FDA Approvals, and Compa …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy pipeline…
Adrenoleukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and C …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy…
Adrenoleukodystrophy Market Size, Market Trends & Analysis till 2033
Market Overview:
The adrenoleukodystrophy market is expected to exhibit a CAGR of 1.84% during 2023-2033. The adrenoleukodystrophy market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major…
